This award recognizes new reviewers who have demonstrated an extraordinary grasp of the public health objectives of FDA’s review process and through their efforts have affected or contributed to a significant regulatory decision of their review unit.
Shruti V. Kabadi, PhD
For outstanding review and analysis of pharmacokinetic data using computational methods to ensure the safe use of food additives and resolve public health issues.
Lian Ma, PhD
For exceptional contribution towards personalized medicine in the area of medical countermeasures and oncology through optimal dose selection and dose individualization.
Michelle L. McClure, PhD
For outstanding achievement in device review, leading to development of guidance on infectious disease screening and testing for donors of human cells and tissue-based products.
Maura C. O’Leary, M.D., CBER
For outstanding review of cell and gene therapies for the treatment of pediatric malignancies.
April Neal Kluever, Ph.D., D.A.B.T., CFSAN
For outstanding performance as a new reviewer in the Division of Food Contact Notifications, OFAS, CFSAN
Eric Dollins, Ph.D., CBER
For outstanding contributions to improving the regulation of innovative products in cellular therapies.
Scott Winiecki, M.D., CBER
For outstanding epidemiologic investigation and analysis of thromboembolic events following the use of intravenous immune globulins, leading to improved safety of currently available medications.
Christopher Breder, M.D., Ph.D., CDER
For development and application of unique methods of analysis and for systematic and innovative review of original data in a complex application
Qiang Xu, Ph.D., CDER
For outstanding contributions in regulatory review work and scientific research work related to science-based decision making process.
Jennifer Catalano, PhD, CBER
For outstanding contribution on the complex issue of review of application with new ‘genomics technologies and International Conference on Harmonization genomics guidance formation 2012